Stock Price

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

A 14th-century Scottish castle is set for a modern makeover as MDJM LTD bets on turning the historic Fernie Castle into a major animation art gallery.

After a period of uncertainty, the digital asset firm has regained compliance with Nasdaq's bid price rule, a key step for its institutional ambitions.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

Despite a stock dip, Select Water Solutions' major offering signals a strategic push for growth in water recycling, acquisitions, and infrastructure.

Seagate retires $600M in debt for cash and stock. A strategic move to fortify its balance sheet, but what does the share dilution mean for investors?

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Facing delisting, the Singaporean tech firm enacts a 1-for-20 reverse split. Is it a lifeline or a sign of deeper financial troubles ahead?

CRCD reports a 4.3% annual return and a higher share price, while shifting its investment model to better support Quebec’s entrepreneurial ecosystem.

The crypto ATM giant is executing a 1:7 reverse stock split to boost its share price. Is it a savvy strategic reset or a sign of deeper troubles?

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

After a volatile market debut, the supersonic flight company hits the NYSE, signaling a new era for high-speed testing and air-launch services.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.